Venetoclax/Venetoclax tablets usage and dosage

Venetoclax/Venetoclax is a targeted drug used to treat specific hematological tumors. Its usage and dosage need to be formulated according to the patient's specific conditions. In particular, the risk of tumor lysis syndrome (TLS) should be fully assessed before use. Before initiating venetoclax therapy, physicians typically perform a thorough assessment of the patient to understand their level of TLS risk and provide appropriate preventive measures, including hydration and antihyperuricemic treatment, before the first dose. These measures are designed to reduce the risk of TLS to ensure patient safety while taking the medication.

For chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), venetoclax is administered on a 5-week ascending dose schedule. The goal of this regimen is to gradually reduce tumor burden and thereby reduce the risk of TLS. In the first week, patients take 20 mg orally daily, increasing to 50 mg in the second week, 100 mg in the third week, 200 mg in the fourth week, and reaching the recommended maximum dose of 400 mg in the fifth week and beyond.

In monotherapy, the recommended dose of venetoclax is 400 mg once daily, with treatment continued until disease progression or unacceptable toxicity. If used in combination with obinutuzumab, administer obinutuzumab starting on Day 1 of Cycle 1, with a specific dose allocation of 100 mg on Day 1, 900 mg on Day 2, and dosing schedules in subsequent cycles. In this regimen, the use of venetoclax will begin on Day 22 of Cycle 1. After completing 5 weeks of accelerated dosing, patients will continue to take 400 mg of venetoclax daily on Day 1 of Cycle 3 until the end of Cycle 12.

If used in combination withRituximab, patients will begin treatment with Rituximab after completing 5 weeks of escalating doses of venetoclax. In each 28-day treatment cycle, Rituximab was administered intravenously at a dose of 375 mg/m² in the first cycle and 500 mg/m² in subsequent cycles. At the same time, starting from day 1 of Rituximab cycle 1, patients need to continue taking venetoclax 400 mg orally daily and continue this administration for 24 months.

For acute myeloid leukemia (AML), the dosage and escalation schedule of venetoclax also depends on the combination with other drugs. The oral dose starts at 100 mg on day 1 of cycle 1, gradually increases to 400 mg on day 3, and is maintained at 400 mg daily thereafter. During this period, patients can take other medications simultaneously, such as azacitidine 75 mg/m² intravenously or subcutaneously daily on days 1-7 of each 28-day cycle, or decitabine 20 mg/m² intravenously on days 1-5, or cytarabine 20 mg/m² subcutaneously on days 1-10.

In short, the usage and dosage of venetoclax need to be carried out under the guidance of a professional doctor to ensure personalized adjustment according to the patient's specific situation and treatment response. Patients should be monitored regularly during the medication period to evaluate the efficacy and timely adjust the treatment plan to ensure the safety and effectiveness of the treatment.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b118a40d-6b56-cee3-10f6-ded821a97018